Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Abcellera Biologics Inc (ABCL)

Abcellera Biologics Inc (ABCL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
AbCellera Biologics (ABCL) Q4 2024 Earnings Call Transcript

ABCL earnings call for the period ending December 31, 2024.

ABCL : 2.44 (+2.52%)
AbCellera Biologics (ABCL) Q3 2024 Earnings Call Transcript

ABCL earnings call for the period ending September 30, 2024.

ABCL : 2.44 (+2.52%)
Should You Follow Insider Buying on This Biotech Penny Stock?

With significant insider purchases and high-profile hedge fund interest, AbCellera is one penny stock to watch.

ABCL : 2.44 (+2.52%)
LLY : 837.57 (-0.59%)
AbCellera Biologics (ABCL) Q2 2024 Earnings Call Transcript

ABCL earnings call for the period ending June 30, 2024.

ABCL : 2.44 (+2.52%)
1 Billionaire-Backed Penny Stock With 421% Upside

Down 96% from all-time highs, AbCellera Biologics is a biotech stock with massive upside potential, given consensus price target estimates.

AAPL : 218.27 (+1.95%)
AMZN : 196.21 (+0.65%)
ABCL : 2.44 (+2.52%)
LLY : 837.57 (-0.59%)
PFE : 26.28 (+0.34%)
MRK : 93.11 (-1.71%)
Billionaires Are Buying These 2 Beaten-Down Stocks. Are They Smart Buys for Your Portfolio?

The Baker brothers are billionaires with a successful track record in the biopharmaceutical industry.

MRK : 93.11 (-1.71%)
LLY : 837.57 (-0.59%)
PFE : 26.28 (+0.34%)
OPHLY : 3.7700 (+2.17%)
ABCL : 2.44 (+2.52%)
FATE : 0.9139 (-2.43%)
Down 57%, Is AbCellera Biologics a Buy on the Dip?

Wall Street analysts say this drug developer can more than double your money.

LLY : 837.57 (-0.59%)
ABCL : 2.44 (+2.52%)
AbCellera Biologics (ABCL) Q1 2024 Earnings Call Transcript

ABCL earnings call for the period ending March 31, 2024.

ABCL : 2.44 (+2.52%)
3 AI-Driven Drug Stocks to Buy Before They Breakout

The pharma sector is expected to undergo a huge disruption, thanks to the impact of artificial intelligence. Here are three companies that Wall Street analysts think could benefit, based on their AI-driven...

NVDA : 117.70 (-0.70%)
GOOGL : 163.99 (+0.73%)
AMZN : 196.21 (+0.65%)
GS : 565.14 (+0.44%)
ABCL : 2.44 (+2.52%)
REGN : 658.48 (-0.62%)
MRNA : 32.66 (+0.65%)
LLY : 837.57 (-0.59%)
NVS : 112.13 (-0.95%)
SDGR : 21.80 (-2.15%)
BMY : 61.07 (+1.08%)
ABSI : 3.01 (-0.99%)
AbCellera Biologics (ABCL) Q4 2023 Earnings Call Transcript

ABCL earnings call for the period ending December 31, 2023.

ABCL : 2.44 (+2.52%)

Barchart Exclusives

Nvidia CEO Jensen Huang Is Betting on $1 Trillion in Data Center Buildouts By 2028. Here’s the Top Stock to Buy.
The stock of Nvidia’s only genuine competitor could benefit from the upcoming data center boom. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar